{"product_id":"essential-guide-to-blood-coagulation-isbn-9781118288795","title":"Essential Guide to Blood Coagulation","description":"\u003cp\u003e\u003cb\u003eA practical guide to laboratory diagnosis and treatment of hemostatic disorders.\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003eThis concise book distils the most clinically up-to-date information on thrombotic and bleeding disorders, including the latest treatment strategies, for key conditions and diseases. \u003ci\u003eEssential Guide to Blood Coagulation\u003c\/i\u003e covers both the stable and the acute stages of hereditary and acquired bleeding and thrombotic disorders.\u003c\/p\u003e \u003cp\u003eFaced with a bleeding patient, it may be difficult to determine whether blood loss is due to a local factor, or an underlying hemostatic defect. There are a range of laboratory tests which can be performed to identify the cause of bleeding in a patient. This book highlights the tests that can be used in the laboratory to aid diagnosis.\u003c\/p\u003e \u003cp\u003e\u003ci\u003eEssential Guide to Blood Coagulation\u003c\/i\u003e has been updated to include the new anticoagulants and now has a dedicated chapter on antiplatelet drugs. This invaluable guide will help all those treating patients to expand their knowledge of hemostatic disorders.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eTITLES OF RELATED INTEREST\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eHemophilia and Hemostasis: A Case-Based Approach to Management\u003c\/b\u003e\u003cbr\u003e\u003cb\u003eSecond Edition\u003c\/b\u003e\u003cbr\u003eAlice Ma, Harold Roberts, Miguel Escobar\u003cbr\u003eISBN: 978-0-470-65976-2\u003c\/p\u003e \u003cp\u003e\u003cb\u003eQuality in Laboratory Hemostasis and Thrombosis\u003c\/b\u003e\u003cbr\u003e\u003cb\u003eSecond Edition\u003c\/b\u003e\u003cbr\u003eSteve Kitchen, John Olson, Eric Preston (due May 2013)\u003cbr\u003eISBN: 978-0-470-67119-1\u003c\/p\u003e  \u003cp\u003eList of contributors, x\u003c\/p\u003e \u003cp\u003ePreface, xii\u003c\/p\u003e \u003cp\u003eAbbreviations, xiii\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART 1: GENERAL HEMOSTASIS\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Schematic presentation of the hemostatic system, 3\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eNils Egberg\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Proposals for sampling instructions, 6\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eMargareta Blombäck and Nils Egberg\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003ePoints to note prior to sampling, 6\u003c\/p\u003e \u003cp\u003eSampling time and patient preparation, 7\u003c\/p\u003e \u003cp\u003eReferrals for coagulation analyses, 8\u003c\/p\u003e \u003cp\u003eSampling, 8\u003c\/p\u003e \u003cp\u003eTechnique, 9\u003c\/p\u003e \u003cp\u003eFor DNA investigation (genetic analyses), 10\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Laboratory investigations, 11\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eJovan P. Antovic, Liselotte Onelöv, and Nils Egberg\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eNomenclature, 11\u003c\/p\u003e \u003cp\u003eReference intervals for laboratory investigations, 13\u003c\/p\u003e \u003cp\u003eScreening analyses, 13\u003c\/p\u003e \u003cp\u003eSpecial analyses, 20\u003c\/p\u003e \u003cp\u003eMarkers of coagulation activation (hypercoagulation markers), 29\u003c\/p\u003e \u003cp\u003eDNA analyses, 29\u003c\/p\u003e \u003cp\u003eGlobal hemostatic assays and bedside methods, 31\u003c\/p\u003e \u003cp\u003eUseful components in research studies, 32\u003c\/p\u003e \u003cp\u003ePlatelet-activating predictors, 35\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART 2: BLEEDING DISORDERS\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Hereditary bleeding disorders, 41\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eMargareta Holmström and Lars Göran Lundberg\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eGeneral remarks about hemophilia A and B, 41\u003c\/p\u003e \u003cp\u003eGeneral remarks about von Willebrand disease, 42\u003c\/p\u003e \u003cp\u003eFactor concentrates used for treatment of hemophilia A and B and VWD in Sweden in 2012, 43\u003c\/p\u003e \u003cp\u003eTreatment strategy in severe forms of hemophilia and VWD, 44\u003c\/p\u003e \u003cp\u003eRecommendations for desired initial plasma concentrations at different types of bleedings, 45\u003c\/p\u003e \u003cp\u003eSurgery in patients with bleeding disorders, 47\u003c\/p\u003e \u003cp\u003eTooth extraction in a hemophilia patient, 47\u003c\/p\u003e \u003cp\u003eCaution in patients with bleeding disorders, 48\u003c\/p\u003e \u003cp\u003eTreatment principles for different types of bleeding disorders (severe, moderate, and milder forms of hemostatic defects), 49\u003c\/p\u003e \u003cp\u003eRare bleeding disorders, 51\u003c\/p\u003e \u003cp\u003eBlood sampling in bleeding disorders, 54\u003c\/p\u003e \u003cp\u003eBleeding risk charts, 54\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Critical bleeding, 56\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eMaria Bruzelius, Anna Ågren, and Hans Johnsson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 56\u003c\/p\u003e \u003cp\u003eDefinition of massive bleeding, 56\u003c\/p\u003e \u003cp\u003eTransfusion coagulopathy, 56\u003c\/p\u003e \u003cp\u003eRecommendations to obtain optimal hemostasis, 57\u003c\/p\u003e \u003cp\u003eChoice of plasma, 58\u003c\/p\u003e \u003cp\u003eLocal procedures, 59\u003c\/p\u003e \u003cp\u003eAdditional treatment, 59\u003c\/p\u003e \u003cp\u003eFibrinogen concentrate, 59\u003c\/p\u003e \u003cp\u003eProthrombin-complex concentrate (PCC), 59\u003c\/p\u003e \u003cp\u003eRecombinant factor VIIa, 59\u003c\/p\u003e \u003cp\u003eConcentrates of other coagulation factors, 60\u003c\/p\u003e \u003cp\u003eCryoprecipitates, 60\u003c\/p\u003e \u003cp\u003eTranexamic acid, 60\u003c\/p\u003e \u003cp\u003eDesmopressin, 60\u003c\/p\u003e \u003cp\u003eLocal hemostatic drugs, 60\u003c\/p\u003e \u003cp\u003eComplicating factors, 61\u003c\/p\u003e \u003cp\u003eOngoing treatment with antiplatelet, and anticoagulant drugs, 61\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Investigation of increased bleeding tendency, 62\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eMargareta Holmström and Lars Göran Lundberg\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 62\u003c\/p\u003e \u003cp\u003eDiagnosis, 62\u003c\/p\u003e \u003cp\u003eReasons for pathologic screening analyses and further actions, 64\u003c\/p\u003e \u003cp\u003eCauses of thrombocytopenia, 64\u003c\/p\u003e \u003cp\u003eCauses of prolonged activated partial thromboplastin time, 65\u003c\/p\u003e \u003cp\u003eCauses of elevated PT(INR), 66\u003c\/p\u003e \u003cp\u003eInvestigation of bleeding tendency: practical aspects, 66\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART 3: THROMBOEMBOLIC DISORDERS\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Venous thrombosis and pulmonary embolism, 71\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eAnders Carlsson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 71\u003c\/p\u003e \u003cp\u003eVenous thrombosis, 72\u003c\/p\u003e \u003cp\u003ePulmonary embolism, 75\u003c\/p\u003e \u003cp\u003ePrimary prophylaxis against VTE, 91\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Investigations of thromboembolic tendency, 94\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eMargareta Holmström\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 94\u003c\/p\u003e \u003cp\u003eVenous thromboembolism, 95\u003c\/p\u003e \u003cp\u003eArterial thromboembolism, 96\u003c\/p\u003e \u003cp\u003eDisseminated intravascular coagulation, 96\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Heart disease, 97\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eHåkan Wallen and Rickard Linder\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIschemic heart disease, 97\u003c\/p\u003e \u003cp\u003eAtrial fibrillation, 102\u003c\/p\u003e \u003cp\u003eCardiac valve prosthesis, 103\u003c\/p\u003e \u003cp\u003eNew oral anticoagulants in the treatment of heart disease, 104\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Antiplatelet drug therapy and reversal of its effects, 105\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eHåkan Wallen, Hans Johnsson, and Bo-Michael Bellander\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 105\u003c\/p\u003e \u003cp\u003eASA, 105\u003c\/p\u003e \u003cp\u003eADP (P2Y12) receptor antagonists, 106\u003c\/p\u003e \u003cp\u003eGPIIb\/IIIa receptor antagonists, 106\u003c\/p\u003e \u003cp\u003ePhosphodiesterase inhibitors and other antiplatelet compounds, 108\u003c\/p\u003e \u003cp\u003eCombined antithrombotic treatment, 108\u003c\/p\u003e \u003cp\u003eBenefi t–risk assessment, 108\u003c\/p\u003e \u003cp\u003ePlatelet transfusion, 109\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 New oral anticoagulants: Focus on currently approved oral factor Xa and Thrombin inhibitors, 111\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eRickard E. Malmström and Hans Johnsson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eClinical pharmacology of NOACs, 111\u003c\/p\u003e \u003cp\u003ePossibility of and need for therapeutic monitoring of NOACs, 114\u003c\/p\u003e \u003cp\u003eClinical aspects of NOACs, 114\u003c\/p\u003e \u003cp\u003eResults of clinical trials, 116\u003c\/p\u003e \u003cp\u003eSome characteristics of the individual NOACs, 118\u003c\/p\u003e \u003cp\u003eConsiderations to be taken when using NOACs in some emergency situations\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Stroke and transient ischemic attack, 121\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eNils Wahlgren and Mia von Euler\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAntithrombotic secondary stroke prevention, 121\u003c\/p\u003e \u003cp\u003eAtrial fibrillation and TIA or stroke, 122\u003c\/p\u003e \u003cp\u003eThrombolysis in stroke, 122\u003c\/p\u003e \u003cp\u003eCerebral venous thrombosis and dissection of precerebral arteries, 123\u003c\/p\u003e \u003cp\u003eRecurrent TIA, 124\u003c\/p\u003e \u003cp\u003eProphylactic treatment against DVT and PE, 124\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Peripheral artery surgery, 125\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eJesper Swedenborg\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eProphylaxis against reocclusion in peripheral vascular surgery or percutaneous transluminal angioplasty (PTA), 125\u003c\/p\u003e \u003cp\u003ePeri- and postoperative treatment, 125\u003c\/p\u003e \u003cp\u003eThrombolysis in acute ischemia, 126\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART 4: SPECIAL HEMOSTASIS\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Hemostasis in obstetrics and gynecology, 129\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eKatarina Bremme\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 129\u003c\/p\u003e \u003cp\u003eThrombosis during pregnancy, 131\u003c\/p\u003e \u003cp\u003eHeart disease: treatment of women with mechanical heart valve prostheses, 139\u003c\/p\u003e \u003cp\u003eThromboprophylaxis in obstetrics and gynecology, 140\u003c\/p\u003e \u003cp\u003eBlood sampling in children of women with severe forms of thrombophilia, 148\u003c\/p\u003e \u003cp\u003eObstetric epidural\/spinal analgesia (anesthesia), 148\u003c\/p\u003e \u003cp\u003eComplications during pregnancy, 150\u003c\/p\u003e \u003cp\u003ePostpartum bleeding, 155\u003c\/p\u003e \u003cp\u003eThromboprophylaxis in legal and spontaneous abortions, 156\u003c\/p\u003e \u003cp\u003eThromboprophylaxis in gynecologic surgery, 156\u003c\/p\u003e \u003cp\u003eInvestigation prior to artificial insemination (IVF), 160\u003c\/p\u003e \u003cp\u003eInvestigation in repeated miscarriages, 160\u003c\/p\u003e \u003cp\u003eInvestigation in menorrhagia (for treatment see Chapter 4), 161\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Hemostasis in children, 162\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eSusanna Ranta and Pia Petrini\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 162\u003c\/p\u003e \u003cp\u003eBleeding disorders in children, 166\u003c\/p\u003e \u003cp\u003eThromboembolic disorders in children, 172\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Emergency conditions associated with coagulation: DIC, HIT and TTP\/HUS, 182\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eJovan P. Antovic and Margareta Holmström\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eDisseminated intravascular coagulation, 182\u003c\/p\u003e \u003cp\u003eHeparin-induced thrombocytopenia, 188\u003c\/p\u003e \u003cp\u003eThrombotic microangiopathies, 190\u003c\/p\u003e \u003cp\u003eIndex, 191\u003c\/p\u003e  \u003cp\u003e“Nevertheless, this book could one day become the ‘oxford handbook’ – equivalent for coagulation.”  (\u003ci\u003eThe Haem Trainee\u003c\/i\u003e\u003ci\u003e,\u003c\/i\u003e \u003ci\u003e1 August2013)\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e“This book would be useful to those wanting an introduction to coagulation disorders. More experienced practitioners will likely find its treatment of coagulation disorders too superficial for their needs.”  (\u003ci\u003eDoody’s\u003c\/i\u003e, 23 August 2013)\u003c\/p\u003e  Edited by\u003cbr\u003e \u003cb\u003eJovan P. Antovic and Margareta Blombäck\u003c\/b\u003e\u003cbr\u003e Department of Molecular Medicine and Surgery, Coagulation Research, Karolinska Institutet; Clinical Chemistry, Karolinska University Hospital,\u003cbr\u003e Stockholm, Sweden \u003cp\u003e\u003cb\u003eA practical guide to laboratory diagnosis and treatment of hemostatic disorders.\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003eThis concise book distils the most clinically up-to-date information on thrombotic and bleeding disorders, including the latest treatment strategies, for key conditions and diseases. \u003ci\u003eEssential Guide to Blood Coagulation\u003c\/i\u003e covers both the stable and the acute stages of hereditary and acquired bleeding and thrombotic disorders.\u003c\/p\u003e \u003cp\u003eFaced with a bleeding patient, it may be difficult to determine whether blood loss is due to a local factor, or an underlying hemostatic defect. There are a range of laboratory tests which can be performed to identify the cause of bleeding in a patient. This book highlights the tests that can be used in the laboratory to aid diagnosis.\u003c\/p\u003e \u003cp\u003e\u003ci\u003eEssential Guide to Blood Coagulation\u003c\/i\u003e has been updated to include the new anticoagulants and now has a dedicated chapter on antiplatelet drugs. This invaluable guide will help all those treating patients to expand their knowledge of hemostatic disorders.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eTITLES OF RELATED INTEREST\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eHemophilia and Hemostasis: A Case-Based Approach to Management\u003c\/b\u003e\u003cbr\u003e\u003cb\u003eSecond Edition\u003c\/b\u003e\u003cbr\u003eAlice Ma, Harold Roberts, Miguel Escobar\u003cbr\u003eISBN: 978-0-470-65976-2\u003c\/p\u003e \u003cp\u003e\u003cb\u003eQuality in Laboratory Hemostasis and Thrombosis\u003c\/b\u003e\u003cbr\u003e\u003cb\u003eSecond Edition\u003c\/b\u003e\u003cbr\u003eSteve Kitchen, John Olson, Eric Preston (due May 2013)\u003cbr\u003eISBN: 978-0-470-67119-1\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989156118757,"sku":"NP9781118288795","price":87.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781118288795.jpg?v=1761783022","url":"https:\/\/k12savings.com\/es\/products\/essential-guide-to-blood-coagulation-isbn-9781118288795","provider":"K12savings","version":"1.0","type":"link"}